Gerber reboots whey protein formula petition
This article was originally published in The Tan Sheet
Executive SummaryNestle Infant Nutrition asks FDA to allow a qualified health claim that 100-percent whey-protein partially hydrolyzed infant formula "may reduce the risk of developing the most common allergic disease of infancy -- atopic dermatitis" in infants not exclusively breastfed. The subsidiary of Florham Park, N.J.-based Gerber Products adds in a May 14 citizen 1petition that partially hydrolyzed formulas are not meant to treat existing food allergy symptoms. FDA posted the petition July 21. In 2005, FDA denied a request by Nestle Infant Nutrition, then a Nestle USA division, for a food allergy QHC for whey protein formula (2"The Tan Sheet" May 22, 2006). The firm says its resubmitted petition has a reworded claim and includes additional supporting science
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.